Future bioenergy trade in the EU: modelling trading options from a cost-effectiveness perspective

被引:10
|
作者
Hansson, Julia [1 ]
Berndes, Goran [1 ]
机构
[1] Chalmers, Environm & Energy Dept, SE-41296 Gothenburg, Sweden
关键词
Bioenergy trade; Biofuels; Electricity; CO(2) credits; EU; BIOMASS; FUEL; SCENARIOS; EUROPE;
D O I
10.1016/j.jclepro.2009.04.005
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
The purpose of this paper is to analyse under what conditions, with respect to CO(2) emission-reduction and biofuels-for-transport targets, the trading in the EU of CO(2) credits and solid and/or liquid biofuels is cost-effective from the perspective of an optimisation energy systems model. We use the PEEP model covering the EU27 (except Bulgaria, Malta, and Cyprus) to generate insights about the cost-effectiveness of different options under different policy scenarios. Trade in CO(2) credits is a cost-effective option, in all relevant policy scenarios. Trade in some biofuels (mainly from central and eastern European countries to the EL15) is cost-effective in all assessed scenarios. In the case of CO(2) targets (whether national or at the EU level) there is trade in solid biofuels. When biofuels-for-transport targets are also implemented, trading both solid and liquid biofuels is cost-effective. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S27 / S36
页数:10
相关论文
共 50 条
  • [1] MODELLING UNCERTAIN FUTURE EVENTS IN COST-EFFECTIVENESS ANALYSIS
    Mahon, R.
    VALUE IN HEALTH, 2013, 16 (07) : A592 - A592
  • [2] COST-EFFECTIVENESS - FROM WHOSE PERSPECTIVE
    HILLMAN, AL
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : S14 - S18
  • [3] Cost-effectiveness modelling
    Barlow, DH
    HUMAN REPRODUCTION, 2001, 16 (12) : 2479 - 2480
  • [4] Modelling cost-effectiveness in osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    BONE, 2008, 43 (01) : 215 - 216
  • [5] Modelling for cost-effectiveness analysis
    Russell, LB
    STATISTICS IN MEDICINE, 1999, 18 (23) : 3235 - 3244
  • [6] COST-EFFECTIVENESS AND THE FUTURE OF MEDICINE
    SHULKIN, DJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (01): : 40 - 40
  • [7] Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
    Dowdy, D. W.
    Houben, R.
    Cohen, T.
    Pai, M.
    Cobelens, F.
    Vassall, A.
    Menzies, N. A.
    Gomez, G. B.
    Langley, I.
    Squire, S. B.
    White, R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (09) : 1012 - 1018
  • [8] COST-EFFECTIVENESS OF FREMANEZUMAB FROM A SOCIETAL PERSPECTIVE IN ENGLAND
    Skroumpelos, A.
    Freddi, M.
    Akcicek, H.
    Cohen, J. M.
    Driessen, M. T.
    VALUE IN HEALTH, 2021, 24 : S162 - S163
  • [9] Cost-effectiveness of lipegfilgrastim from the Mexican payer perspective
    Szende, A.
    Bussey, B.
    Szabo, E.
    Klastersky, J.
    Tomey, O.
    Mueller, U.
    Gabriel, S.
    Tang, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S117 - S117
  • [10] Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study
    Lovibond, Kate
    Jowett, Sue
    Barton, Pelham
    Caulfield, Mark
    Heneghan, Carl
    Hobbs, F. D. Richard
    Hodgkinson, James
    Mant, Jonathan
    Martin, Una
    Williams, Bryan
    Wonderling, David
    McManus, Richard J.
    LANCET, 2011, 378 (9798): : 1219 - 1230